[1] Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer. 1999; 80(6):827-841. [2] 周有尚,张思维.我国人口死亡和恶性肿瘤死亡情况分析[J].中国肿瘤,1997,6(10):9-12.[3] Maehara Y, Moriguchi S, Kakeji Y, et al. Pertinent risk factors and gastric carcinoma with synchronous peritoneal dissemination or liver metastasis. Surgery. 1991;110(5): 820-823. [4] Yoo CH, Noh SH, Shin DW, et al. Recurrence following curative resection for gastric carcinoma. Br J Surg. 2000; 87(2):236-242. [5] 陆枫林,陆亚琴.腹腔化疗前后对腹水端粒酶活性影响研究[J].中华消化杂志,2004,24(2):110-111.[6] Elias D, Bonnay M, Puizillou JM, et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol. 2002;13(2):267-272. [7] 王江.比较顺铂不同给药方式对腹膜移植瘤的影响[J].中国实用医药,2007,2(16):11-13.[8] 唐贺文.活性碳吸附丝裂霉素C腹腔化疗的药代动力学研究[D].天津:天津医科大学,2002:1-76. [9] Shanmuganathan S, Shanmugasundaram N, Adhirajan N, et al. Preparation and characterization of chitosan microspheres for doxycycline delivery. Cabohydr Polym. 2008;73(2): 201-211.[10] Park SH, Chun MK, Choi HK. Preparation of an extended-release matrix tablet using chitosan/Carbopol interpolymer complex. Int J Pharm. 2008;347(1-2):39-44. [11] Tomlinson E. Site-specific drug carriers. Eng Med. 1986;15(4):197-202. [12] Gavrilov K, Saltzman WM. Therapeutic siRNA: principles, challenges, and strategies. Yale J Biol Med. 2012; 85(2): 187-200. [13] 中国知网.中国学术期刊总库[DB/OL].2012-11-16. https://www.cnki.net.[14] 易兵鸿.5-氟脲嘧啶壳聚糖缓释微球抑制裸鼠腹腔种植胃癌细胞生长的实验研究[D].江西:南昌大学,2010:1-31.[15] 马菲菲.应用载药微球局部化疗治疗胃癌的实验性研究[D].天津:天津医科大学,2008:1-62. [16] 黄开红,赵晓龙,朱兆华,等.5-氟尿嘧啶聚乳酸载药纳米微粒对人胃癌和结肠癌细胞株的体外杀伤效应[J].中国实验外科杂志, 2005,22(5):606-608.[17] 胡云霞,原续波,张晓金,等.聚乳酸载药纳米微粒的表面修饰及体外评价[J].中国生物医学工程学报,2004,23(1):30-36.[18] 李勇,刘滨伟,杜文力,等.复方氟脲嘧啶的术前腹腔应用及其在胃癌组织中的分布[J].中华肿瘤杂志,2004,26(10):638-640.[19] 张浩.淋巴靶向抗癌药物卡波霉素载体制备方法优化及药效研究[D].北京:中国人民解放军军事医学科学院,2011:1-76.[20] 张李.纳米炭吸附丝裂霉素C腹腔化疗的药代动力学研究[D].天津:天津医科大学,2007:1-52.[21] 朱共元.几丁糖—顺铂缓释药膜抑制胃癌腹膜亚临床转移的实验研究[D].江西:南昌大学,2009:1-39.[22] 魏玉亮.几丁糖—顺铂缓释药膜的制备及体外抑制胃癌细胞生长的研究[D].江西:南昌大学,2008:1-31.[23] 秦仁义,裘法祖.纳米生物技术在实验外科的应用前景[J].中华实验外科杂志,2003,20(9):773-775.[24] 周平红,姚礼庆,秦新裕,等.磁性阿霉素纳米脂质体的研制及其磁靶向定位研究[J].中华实验外科杂志,2004,21(4):492.[25] Mukherji G, Murthy RSR, Miglani BD. Preparation and evaluation of polyglutaraldehyde nanoparticles containing 5-fluorouracil. Int J Pharm. 1989;50:15-19. [26] 郑连英,朱江峰,孙昆山.壳聚糖的抗菌性能研究[J].材料科学与工程,2000,18(2):22-24.[27] 王红昌,孙晓飞.不同分子量高脱乙酰度壳聚糖的制备及表征[J].中国海洋药物,2007,26(1):16-19.[28] Seyfarth F, Schliemann S, Elsner P, et al. Antifungal effect of high- and low-molecular-weight chitosan hydrochloride, carboxymethyl chitosan, chitosan oligosaccharide and N-acetyl- D-glucosamine against Candida albicans, Candida krusei and Candida glabrata. Int J Pharm. 2008;353(1-2):139-148. [29] 陈威,吴清平,张菊梅,等.壳聚糖抑菌机制的初步研究[J].微生物学报,2008,48(2):164-168.[30] 宋永焕,刘一,于铁成,等.壳聚糖纳米颗粒免疫刺激作用的初步研究[J].浙江医学,2008,30(11):1208-1210.[31] Cho EJ, Rahman MA, Kim SW, et al. Chitosan oligosaccharides inhibit adipogenesis in 3T3-L1 adipocytes. J Microbiol Biotechnol. 2008;18(1):80-87. [32] 房国坚,蒋玉燕,毕忆群,等.壳聚糖纳米混悬剂抗突变生物学效应:原核细胞基因突变试验[J].中国组织工程研究与临床康复, 2008,12(45):8867-8869.[33] Frasci G, Iaffaioli RV, Comella G, et al. Intraperitoneal adjuvant immunochemotherapy in operable gastric cancer with serosal involvement. Clin Oncol (R Coll Radiol). 1994; 6(6):364-370. [34] 梁寒,王殿昌,张高嘉.胃镜下胃粘膜注墨32例临床应用[J].重庆医学,1998,27(增):265-266.[35] Hagiwara A. Mitomycin C adsorbed to activated carbon particles as a new drug dosage form for cancer chemotherapy. Akita J Med. 1983;10:187-189.[36] 梁寒,王殿昌,孙慧,等.活性碳吸附丝裂霉素C腹腔化疗的临床实验研究[J].中国肿瘤临床,2000,27(12):897-901.[37] Shimotsuma M, Shields JW, Simpson-Morgan MW, et al. Morpho-physiological function and role of omental milky spots as omentum-associated lymphoid tissue (OALT) in the peritoneal cavity. Lymphology. 1993;26(2):90-101. [38] Felt O, Buri P, Gurny R. Chitosan: a unique polysaccharide for drug delivery. Drug Dev Ind Pharm. 1998;24(11):979-993. [39] Felt O, Furrer P, Mayer JM, et al. Topical use of chitosan in ophthalmology: tolerance assessment and evaluation of precorneal retention. Int J Pharm. 1999;180(2):185-193. [40] Yuan Y, Zhang P, Yang Y, et al. The interaction of Schwann cells with chitosan membranes and fibers in vitro. Biomaterials. 2004;25(18):4273-4278. [41] Mi FL, Tan YC, Liang HF, et al. In vivo biocompatibility and degradability of a novel injectable-chitosan-based implant. Biomaterials. 2002;23(1):181-191. [42] 田冶,焦延鹏,陈义康,等.不同脱乙酰度对壳聚糖表面物理及吸附性能的影响[J].广州化学,2005,30(2):20-25.[43] Bonelli P, Tuccillo FM, Federico A, et al. Ibuprofen delivered by poly(lactic-co-glycolic acid) (PLGA) nanoparticles to human gastric cancer cells exerts antiproliferative activity at very low concentrations. Int J Nanomedicine. 2012;7: 5683-5691.[44] Liu P, Wang H, Wang Q, et al. cRGD conjugated mPEG-PLGA-PLL nanoparticles for SGC-7901 gastric cancer cells-targeted Delivery of fluorouracil. J Nanosci Nanotechnol. 2012;12(6):4467-4471.[45] Harada M, Iwata C, Saito H, et al. NC-6301, a polymeric micelle rationally optimized for effective release of docetaxel, is potent but is less toxic than native docetaxel in vivo. Int J Nanomedicine. 2012;7:2713-2727. [46] Li CJ, Chu CY, Huang LH, et al. Synergistic anticancer activity of triptolide combined with cisplatin enhances apoptosis in gastric cancer in vitro and in vivo. Cancer Lett. 2012;319(2): 203-213.[47] Zhang J, Zhu JS, Zhou Z, et al. Inhibitory effects of ethyl pyruvate administration on human gastric cancer growth via regulation of the HMGB1-RAGE and Akt pathways in vitro and in vivo. Oncol Rep. 2012;27(5):1511-1519. [48] Shapira A, Davidson I, Avni N, et al. β-Casein nanoparticle-based oral drug delivery system for potential treatment of gastric carcinoma: stability, target-activated release and cytotoxicity. Eur J Pharm Biopharm. 2012;80(2):298-305. [49] Vaghani S, Vasanti S, Chaturvedi K, et al. Stomach-specific drug delivery of 5-fluorouracil using ethylcellulose floating microspheres. Pharm Dev Technol. 2010;15(2):154-161. [50] Prabu P, Chaudhari AA, Aryal S, et al. In vitro evaluation of poly(caporlactone) grafted dextran (PGD) nanoparticles with cancer cell. J Mater Sci Mater Med. 2008;19(5): 2157-2163.[51] Manfredi S, Pagenault M, de Lajarte-Thirouard AS, et al. Type 1 and 2 gastric carcinoid tumors: long-term follow-up of the efficacy of treatment with a slow-releasesomatostatin analogue. Eur J Gastroenterol Hepatol. 2007;19(11): 1021-1025.[52] Chen SH, Lin KY, Chang CC, et al. Aloe-emodin-induced apoptosis in human gastric carcinoma cells. Food Chem Toxicol. 2007;45(11):2296-2303. [53] 王银松,李英霞,宋妮,等.靶向抗肿瘤药物甲氨喋呤—琥珀酰壳聚糖缀合物的制备及其体外稳定性的初步探讨[J].高等学校化学学报,2003,24(11):2103-2106.[54] 黄园,袁芳,张志荣.肿瘤靶向给药系统的研究进展[J].华西药学杂志,2006,21(6):566-569.[55] Ikehara Y, Niwa T, Biao L, et al. A carbohydrate recognition-based drug delivery and controlled release system using intraperitoneal macrophages as a cellular vehicle. Cancer Res. 2006;66(17):8740-8748. |